ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olaparib

Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.

Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.

Drug pageOlaparib: every studyMany companies study it; this page follows only the 76 they lead. All 323 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 10, 201576 company-led studies, 22 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only5915 open or runningphase 4since Jun 10, 2015Jun 27, 2007Apr 6, 2027phase 3 · NCT04421963
Merckits history only125 open or runningphase 3since Mar 29, 2018Aug 3, 2016May 5, 2027phase 3 · NCT04380636
Novartisits history only20 open or runningphase 3since Jan 25, 2021Jan 25, 2021none ahead
Boryung Pharmaceutical11 open or runningphase 1since Jul 7, 2025Jul 7, 2025none ahead
CSPC Pharmaceutical Groupits history only10 open or runningphase 1since Apr 7, 2024Apr 7, 2024none ahead
Daewoong Pharmaceuticalits history only11 open or runningphase 1since Jan 19, 2026Jan 19, 2026Mar 2027phase 1 · NCT07371104

Also a collaborator on its studies: Myriad Genetic Laboratories, Frontier Science & Technology Research Foundation, Hoffmann-La Roche, Myriad Genetics, Iqvia Pty, Covance, Theradex, Parexel and KuDOS Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boryung Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 7, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT07069335 · 24 planned · South Korea

TargetBeta

“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule

Studies

The one study Boryung Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07069335Ovarian Neoplasms · South Korea1RecruitingMay 15, 202624

How it is read

Names in the registry

  • “Olaparib”, 38 entries
  • “olaparib”, 10 entries
  • “AZD2281”, 10 entries
  • “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
  • “Olaparib 300mg tablets”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.